We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00231790
First Posted: October 4, 2005
Last Update Posted: December 17, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
Overactive bladder is very prevalent in postmenopausal women. The current study is designed to investigate whether a new drug may offer safe and effective treatment.

Condition Intervention Phase
Urinary Incontinence Drug: MK-0634 50 mg Drug: MK-0634 125 mg Drug: Placebo for MK-0634 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of MK0634 in Postmenopausal Women With Overactive Bladder

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Change from baseline in the number of micturitions per day averaged over a diary card week (4 to 10 days) [ Time Frame: Baseline and Week 8 ]
  • Proportion of participants with abnormal retinal photography (Follow-up Study 007 only) [ Time Frame: Day 1 of Follow-up ]
  • Proportion of participants with abnormal visual field test (Follow-up Study 007 only) [ Time Frame: Day 1 of Follow-up ]

Secondary Outcome Measures:
  • Change from baseline in the number of total incontinence episodes [ Time Frame: Baseline and Week 8 ]
  • Number of urge-incontinence episodes [ Time Frame: Up to 8 weeks ]
  • Number of urgency episodes per day averaged over a diary card week (4 to 10 days) [ Time Frame: up to 8 weeks ]

Enrollment: 848
Study Start Date: August 2005
Study Completion Date: October 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MK-0634 50 mg
All participants will receive placebo for the 1 week prior to randomization
Drug: MK-0634 50 mg
one capsule orally, once daily in morning
Other Name: L-000796568
Experimental: MK-0634 125 mg
All participants will receive placebo for the 1 week prior to randomization
Drug: MK-0634 125 mg
one or three capsules orally, once daily in morning
Other Name: L-000796568
Experimental: MK-0634 375 mg
All participants will receive placebo for the 1 week prior to randomization
Drug: MK-0634 125 mg
one or three capsules orally, once daily in morning
Other Name: L-000796568
Placebo Comparator: Placebo
All participants will receive placebo for the 1 week prior to randomization
Drug: Placebo for MK-0634
one, two, three or four capsules orally once daily in morning

Detailed Description:
Clinical development of MK-0634 was discontinued. Study MK-0634-027 was a safety follow-up study to determine if there were any ocular effects of MK-0634 in participants from the United Kingdom who were exposed to MK-0634 during the 007 study.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Postmenopausal females (ages 40-74) with predominantly urge urinary incontinence overactive bladder episodes.
  • Patients must meet minimum eligibility requirements (e.g., average number of micturitions/day) based on screening diary cards.

Exclusion Criteria:

  • Patients must not suffer from diabetes insipidus
  • Hyperglycemia
  • Hypercalcemia
  • Orthostatic hypotension
  • Active/recurrent urinary tract infections (>6 episodes per year)
  • Patients must be willing to discontinue their current OAB medication therapy.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00231790


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00231790     History of Changes
Other Study ID Numbers: 0634-007
2005_045
First Submitted: September 30, 2005
First Posted: October 4, 2005
Last Update Posted: December 17, 2015
Last Verified: December 2015

Additional relevant MeSH terms:
Urinary Incontinence
Enuresis
Urinary Bladder, Overactive
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Behavioral Symptoms
Elimination Disorders
Mental Disorders
Urinary Bladder Diseases